Kommentar zu „Autoimmun-Erkrankung: LDL-Cholesterin-Senkung reduziert kardiovaskuläres Risiko“

10.1055/a-2646-5881

Publication History

Article published online:
10 October 2025

• Literatur

• 1 Mortensen MB, Jensen JM, Rønnow Sand NP. et al. Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events. J Am Coll Cardiol 2024; 83: 2643-2654
• 2 Xie S, Galimberti F, Olmastroni E. et al. for the META-LIPID Group. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive metaanalysis of randomized controlled trials. Cardiovasc Res 2024; 120: 333-344
• 3 Bonaca MP, Nault P, Giugliano RP. et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137: 338-350
• 4 Sabatine MS, Giugliano RP, Keech AC. et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-1722
• 5 Zimerman A, Kunzler ALF, Weber BN. et al. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation 2025; 151: 1467-1476